Akeso, Inc. (09926.HK)

Akeso, Inc. is an investment company engaged in the research and development, production, and sale of biopharmaceutical products. The company is headquartered in Zhongshan, Guangdong, and currently employs 3,529 full-time employees. It went public on April 24, 2020. The company's pipeline covers therapeutic areas including oncology, autoimmune diseases, and metabolic disorders. Its products primarily include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), ligufalimab (AK117, CD47), pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) for oncology; as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and gumokimab (AK111, IL-17) for metabolic and autoimmune therapeutic areas.